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doi:10.1016/j.clim.2008.03.458Abstract Th1 related chemokines CCL3 and CCL5 and Th2 related CCL4 as ligands of the receptor
CCR5contribute todisease development in animalmodels of type 1 diabetes. In humans, nodata are
available addressing the role of these chemokines regarding disease progression and remission. We
investigated longitudinally circulating concentrations of CCR5 ligands of 256 newly diagnosed
patients with type 1 diabetes. CCR5 ligands were differentially associated with β-cell function and
clinical remission. CCL5was decreased in remitters and positively associatedwith HbA1c suggestive
of a Th1 associated progression of the disease. Likewise, CCL3 was negatively related to C-peptide
and positively associated with the β-cell stress marker proinsulin but increased in remitters. CCL4
associated with decreased β-cell stress shown by negative association with proinsulin. Blockage of
chemokines or antagonism of CCR5 by therapeutic agents such as maraviroc may provide a new
therapeutic target to ameliorate disease progression in type 1 diabetes.
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Type 1 diabetes is an immune mediated disease resulting in
selective β-cell destruction. T-cells play a major pathogenic.
58 C. Pfleger et al.role in islet cell infiltration and destruction [1] and express
chemokine receptors on their surface [2]. Chemokines CCL3/
MIP-1alpha, CCL4/MIP-1beta and CCL5/RANTES are the
natural ligands of the CC chemokine receptor 5 (CCR5) and
have been shown to play an important role in immune-
mediated diabetes. In the non-obese diabetic (NOD) mouse,
diabetes could be transferred with T-cell clones secreting
CCL3 and CCL5 that were of Th1 phenotype, whereas cells of
Th2 phenotype that were unable to transfer disease secreted
CCL4 [3]. However, both phenotypes were able to induce
insulitis. Carvalho-Pinto [4] showed that leukocyte attraction
through the CCR5 receptor controls progress from insulitis to
diabetes in NOD mouse. Mice treated with neutralizing anti-
CCR5 antibodies developed periinsulitis but did not progress
to diabetes. These data suggest that chemotaxis via ligands of
CCR5 controls the invasive as well as the destructive potential
of islet infiltrating T-cells. Similarly, in a murine islet trans-
plantation model, BALB/c islet allograft transplanted into
CCR5−/− C57BL/6 recipients survived significantly longer
compared to the CCR5+/+ wildtype C57BL/6 recipients [5].
Interestingly to note, β-cells do also secrete CCL3, CCL4 and
CCL5 in case of stress or cell death (apoptosis) in addition to the
secretion of these chemokines by infiltrating T-cells [4,6–8].
Investigations in humans revealed elevated circulating
CCL3 and CCL4 concentrations in a small cohort of pre-
diabetic patients [9]. In another study circulating CCL3 and
CCL4 concentrations were found elevated in a subgroup of
newly diagnosed patients, but patients with newly diagnosed
type 1 diabetes mellitus showed reduced CCR5 expression
[10].
So far, no human studies in type 1 diabetes have related the
functional capacity of insulin producing β-cells and systemic
concentrations of the CCR5 ligands CCL3, CCL4 and CCL5. The
aim of the current study was to investigate in patients with
recent diagnosed type 1 diabetes 1) the course of circulating
CCL3, CCL4 and CCL5 during the first year after diagnosis
2) whether patients undergoing remission reveal differences
regarding CCL3, CCL4 and CCL5 in comparison to patients not
undergoing remission 3) associations of CCL3, CCL4, and CCL5
with metabolic status and β-cell function.
Materials and methods
Patients
Patientswere recruited consecutively in 18 centres throughout
Europe (n=252) and Japan (n=4) from the Hvidøre Study. The
design and characteristics of the Hvidøre Study has been
explainedelsewhere, [11,12]. In brief, prospective clinical and
biochemical data of one year from diagnosis were available for
256 children and adolescents (134 girls and 122 boys, median
age 9.6years, range 3months to 16.8years) out of 275 initially
investigated patients at baseline (response rate 93.1%).
Exclusion criteria were non-type-1 diabetes (MODY, secondary
diabetes and other), or initial treatment outside the centres
for more than five days. Patients were diagnosed with type 1
diabetes according to the World Health Organisation (WHO)
criteria [13]. The study was performed according to the
criteria of the Helsinki II Declaration and was approved by the
local ethic committee in each centre. All patients (where
applicable), their parents or guardians gave informed consent.Metabolic parameters
Body mass index (BMI) percentiles were used to asses the
influence of adipose tissue which is more accurate in children
and adolescents than the use of BMI. Stimulated serum C-
peptide and proinsulinwereused as amarker ofβ-cell function
and weremeasured in a central facility at one, six, and twelve
months of follow up. Blood samples were obtained 90min after
the ingestion of a standardized liquid meal (Boost drink,
formerly known as Sustacal (237ml or 8FL OZ containing 33g
carbohydrate, 15g protein and 6g fat, 240kcal): 6ml/kg
(maximum 360ml.), Novartis Medical Health, Inc., Minneapo-
lis, MN, USA, www.boost.com) [14,15]. Serum samples were
labeled and frozen at− 20°C until shipment on dry-ice to Steno
Diabetes Center for central determination of C-peptide and
proinsulin.
Serum C-peptide was analyzed by a fluoroimmunometric
assay (AutoDELFIA™ C-peptide, PerkinElmer Life and Analy-
tical Sciences, Inc, Turku, Finland). The sensitivity was below
1pmol/l, the intra-assay coefficient of variation were below
6% at 20pmol/l, and recovery of the standard, added to
plasma before extraction, was about 100% when corrected
for losses inherent in the plasma extraction procedure [12].
Proinsulin was detected by Sandwich ELISA, which deter-
mines total proinsulin immuno-reactivity both proinsulin and
its conversion intermediates. The detection limit is 0.3pmol/l
and the analytical range lies between 0.3–100pmol/l. The
inter-assay precision is below 8.7%.
Glycemic control as assessed by HbA1c was measured at
diagnosis and one, three, six, nine and twelve months after
diagnosis. HbA1c was determined in a central facility by ion-
exchange high-performance liquid chromatography (normal
reference range 4.1–6.4%) at Steno Diabetes Center,
Gentofte, Denmark [11,16].
We used two definitions of remission to classify patients
using HbA1c and insulin requirement six months after
diagnosis. First, a more classical definition of partial remission
was applied with HbA1cb7.5% and daily insulin b0.4U/kg
(remission 7.5) [17]. However, partial remission discriminated
by HbA1cb7.5% is not always indicative for a euglycemic
status. Thereforewe used in addition, also a stricter definition
of partial remission that was HbA1cb6.5% and daily insulin
b0.4U/kg (remission 6.5). For determination of complete
remission, patients would ideally not require any insulin,
however it is recommended to support patients with low doses
of insulin even in case of “complete” transient remission and
therefore such patients were not available.
Cytokines and chemokines
Blood was drawn 90min after ingestion of the standardized
liquid meal by venipuncture according to a standard protocol
[12]. Thereby, an influence of catheterization on possible
local production of inflammatory mediators during the 90min
boost test could be excluded [18].
Serum samples were immediately labeled and frozen at
− 20°C until shipment on dry ice to the German Diabetes
Centre for determination of chemokines. Concentrations
of circulating chemokines CCL4 and CCL5 were measured by
ELISA as described [9,19] using matched antibody pairs
(R&D Systems, Wiesbaden, Germany). CCL3 was determined
59CCL3/CCL4/CCL5, type 1 diabetes and disease progressionby multiplex-bead technology using commercially available
kits (Fluorokine MAP, R&D Systems, Wiesbaden, Germany).
All chemokines were measured in a blind fashion, e.g.
clinical data were not known when measurements were
performed. The detection limits of the assays were 2.0pg/ml
for CCL3, 3.0pg/ml for CCL4, and 255.5pg/ml for CCL5.
Patients with chemokine concentration lower than the
detection limit were assigned a value half of the detection
limit (CCL3 n=64; CCL4 n=0; CCL5 n=0).The immunoassays
showed inter-assay variations below 20% and intra-assay
variations below 10%.
Statistical methods
For longitudinal follow-up, differences between chemokines
concentrations were analyzed first by Friedman test fol-
lowed by Wilcoxon test in case of significance to investigate
differences between two time points.
Association studies were performed with log transformed
chemokine concentrations, C-peptide and proinsulin that
showed a normal (CCL4, CCL5, C-peptide and proinsulin) or
approximately normal distribution (CCL3). Spearman correla-
tion was applied to investigate correlations between cytokines
or between metabolic parameters; multiple regression analy-
sis was used to investigate associations between cytokines and
metabolic parameters. Regression analysis included cytokines
as the dependent variable and C-peptide, proinsulin and
HbA1c or remission 7.5 or remission 6.5 as independent
variables while adjusting for sex, age and BMI percentiles.
In the so called “association analysis” chemokines and
metabolic parameters were analyzed at one time point. In
the “prospective analysis” one month chemokines concen-
trations were associated with metabolic parameters at the
later time points six and twelve months. Associations
reported are descriptive and were not corrected for multiple
testing. Adjustment for BMI percentiles are based on the
2000 CDC growth charts (www.cdc.gov/growthcharts) of the
Centers of Disease Control and Prevention, 1600 Clifton Rd,
Atlanta, GA 30333, USA. Statistical analyses were performed
using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA) and
GraphPad PRISM version 4 for Windows. GraphPad Software,
San Diego California USA, "www.graphpad.com".Figure 1 Circulating chemokine concentrations of patients with typ
using non-parametric test for paired data (Friedman-test) were p=0
comparison of two time points are indicated in the graph. Bars repre
x-axis for each time point.Results
Longitudinal analysis of circulating chemokine
concentrations
CCL3/MIP-1alpha concentrations did not show statistically
significant changes over time despite considerable variation in
some patients (Fig. 1A). The two other CCR5 ligands exhibited
a decrease in circulating concentrations over time. CCL4/MIP-
1beta concentrations decreased fromdiagnosis to six or twelve
months 11% or 13% respectively (p=0.0017, Fig. 1B). CCL5/
RANTES concentrations were also significantly lower at six or
twelve months after diagnosis 23% and 20% respectively
compared to one month after diagnosis (pb0.0001, Fig. 1C).
Correlations between chemokines and between
proinsulin and C-peptide
A close association between the three CCR5 ligands within
individual patientswasobserved.CCL3waspositively correlated
to CCL4 one (r=0.35, p b0.0001), six (r=0.44, pb0.0001), and
twelve months (r=0.42, pb0.0001) after diagnosis as well as to
CCL5 at one (r=0.17, p=0.0188) and six months (r=0.28,
p=0.0003) of the follow up period. CCL4was correlated to CCL5
at all time points (one month r=0.380, pb0.0001; six months
r=0.36, pb0.0001; twelve months r=0.24, p=0.0013).
C-peptide and proinsulin showed a positive relation at
one (r=0.63; pb0.0001), six (r=0.61; pb0.0001), and twelve
(r=0.70; pb0.0001) months after diagnosis.
Associations of cytokines with remission
Patients were classified as remitters or non-remitters and
associations of this classification with CCR5 ligands were in-
vestigated. Patients with incomplete data record with respect
to classification were excluded from analysis. Classification by
the more classical definition remission 7.5 revealed 89 patients
in remission (48 girls and 41 boys,median age 10.3years,median
HbA1catdiagnosis: 10.65%) and161patients not in remission (74
girls and 87 boys, median age 9.4years; median HbA1c at
diagnosis: 11.1%). The stricter definition of remission 6.5 fore 1 diabetes one, six and twelve months after diagnosis. P-values
.0017 for CCL3 and pb0.0001 for CCL5. P-values referring to the
sent medians. Exact values for medians are depicted above the
60 C. Pfleger et al.classification showed 46 patients in remission (28 girls and 18
boys, median age 10.8years, median HbA1c at diagnosis: 10.4%)
and 204 patients not in remission (94 girls and 110 boys, median
age 9.3years; median HbA1c at diagnosis: 11.0%).
While adjusting for sex, age and BMI percentiles, asso-
ciations of CCL3 andCCL5 (but not of CCL4)wereobservedwith
classification of both definitions of remission (Fig. 2). CCL3was
elevated in remitters in comparison to non-remitters, one
month (p=0.017) and twelvemonths after diagnosis (p=0.013)
in remission 7.5 and remission 6.5, respectively. CCL5 wasFigure 2 Circulating chemokine concentrations in patients classif
of remission 7.5: HbA1cb7.5 and b0.4 U/kg daily insulin; remission 6.5
P-values are adjusted for sex, age and BMI percentiles and indicate cro
time. At the four time points where the values were significantly dif
follows, CCL3 one month after diagnosis, rem 7.5 vs non-rem, 18.77 p
19.83 pg/ml vs 13.11 pg/ml; CCL5 after 1month, rem7.5 vs non-rem, 5
rem, 53.45 ng/ml vs 60.33 ng/ml.decreased in remitters one month after diagnosis in both
definitions of remission (p=0.031; p=0.043, remission 7.5 and
6.5, respectively).
Associations and prospective analysis of HbA1c,
stimulated C-peptide and proinsulin with chemokines
To study associations of CCR5 ligands concentrations with
metabolic parameters, we performed association and pro-
spective analyses.ied remitter or non-remitter. Remission refers to the definition
: HbA1cb6.5 and b0.4 U/kg daily insulin. Bars represent medians.
ss sectional statistical significant differences at the corresponding
ferent, the median values for remitters vs non-remitters were as
g/ml vs 12.5 spg/ml; CCL3 after 12 months, rem 6.5 vs non-rem,
2.55 ng/ml vs 64.64 ng/ml; andCCL5 after 1month, rem6.5 vs non-
Table 1A “Association Model”, association of chemokine





CCL3 1 C-peptide −0.448 0.0006
CCL3 1 Proinsulin 0.368 0.014
CCL3 6 C-peptide −0.446 0.002
CCL3 12 C-peptide −0.280. 0.022
CCL4 1 C-peptide −0.100 0.042
CCL4 12 Proinsulin −0.070 0.037
CCL5 1 HbA1c 0.093 0.005
Regression analysis was adjusted for sex, age and BMI percen-
tiles. Given are the resulting coefficients (β) with their
corresponding p-values.
Table 1B “Prospective Model”, prospective analysis with
association of baseline chemokine concentrations (onemonth
after diagnosis) and subsequent course of the disease (i.e.,
metabolic parameters six and twelve months after diagnosis)
Chemokine Metabolic parameters β p-value
1 month CCL3 6 months HbA1c −0.225 0.026
1 month CCL3 6 months C-peptide −0.410 0.007
1 month CCL3 12 months C-peptide −0.345 0.009
1 month CCL3 12 months proinsulin 0.244 0.018
1 month CCL5 12 months proinsulin 0.120 0.007
Regression analysis was adjusted for sex, age and BMI percen-
tiles. Given are the resulting coefficients (β) with their
corresponding p-values.
61CCL3/CCL4/CCL5, type 1 diabetes and disease progressionIn the association model, circulating concentrations of all
three CCR5 ligands revealed associations with metabolic
parameters (Tables 1A and 1B). Circulating concentrations of
Th1 associated CCL3 were negatively associated with C-pep-
tide one, six and twelve months after diagnosis (p=0.0006,
p=0.002 and p=0.022 respectively) and positively related to
proinsulin one month after diagnosis (p=0.014). CCL5 con-
centrations were positively related to HbA1c one month after
diagnosis (p=0.005) (Table 1A). Th2 associated CCL4 revealed
a negative association with proinsulin twelve months after
diagnosis (p=0.037) and with C-peptide one month after
diagnosis (p=0.042).
In the prospective model, only the Th1 associated chemo-
kines CCL3 and CCL5 revealed associations of their baseline
concentrations with later β-cell function and metabolic con-
trol. CCL3 concentrations one month after diagnosis were
negatively associated with C-peptide (p=0.007) and HbA1c
(p=0.026) six months after diagnosis and with C-peptide
(p=0.009) and proinsulin (p=0.018) twelve months after
diagnosis (Table 1B). One month after diagnosis CCL5 con-
centration showed positive association with proinsulin twelve
months after diagnosis (p=0.007).
Chemokine and C-peptide concentrations separated
by centers
It is known fromepidemiological studies that the incidence and
metabolic characteristics of type 1 diabetes varies geographi-
cally [20,21] and therefore we investigated patients for
center differences. Centers showed differences for C-peptide,
HbA1c, and the CCR5 ligands CCL3, CCL4, CCL5 (pb0.0001,
p=0.013, pb0.0001, p=0.0004, pb0.0001 respectively) but
not for age (Fig. 3).
Discussion
CCR5 and its ligands CCL3, CCL4, and CCL5 are thought to
play a role in immune mediated diabetes in several animal
models. We investigated the association of circulating CCL3,
CCL4, and CCL5 with different definitions of remission and β-
cell function in the well characterized prospective Hvidøre
cohort of newly diagnosed juvenile type 1 diabetes patients
during the first year [11,22].Circulating CCR5 ligands were positively correlated with
each other during the investigated time but further analysis
revealed a distinct role of CCL3, CCL4 and CCL5 in type 1
diabetes.
Patients showed decreasing CCL4 and CCL5 concentrations
with highest concentrations one month after diagnosis. In
contrast, CCL3 remained stable during follow up suggestive of
differential regulation of CCR5 ligands early after diagnosis of
type 1 diabetes without general up regulation of systemic
immunemediators confirming a previous study [17]. Although
these observations suggest a change of cytokines overtime, it
is unclear whether this is of clinical or biological meaning.
Due to the considerable overlap of measurements at the
different time points these cytokine measurements do not
qualify as diagnostic markers on an individual basis. However,
they may offer insights on the role of chemokines in type 1
diabetes and our findings such as associations with remission
ormetabolic parameters are in linewith observationsmade in
animal experiments in vivo [4,23,24].
The analysis of patients' subgroups showed that both Th1
related chemokines CCL3 and CCL5 revealed opposite associa-
tions with remission whereas the Th2 related CCL4 was not
associated with remission, regardless whether the more
classical or stricter version of remission was applied. CCL5
showed decreased concentrations in remitters in comparison
to non-remitterswhich is in linewith a recent publications that
describes a key role in the process of leukocyte invasion in
islets [4]. Interestingly, CCL3 which attracts leukocytes to the
site of inflammation [25] was elevated in remitters. This
observation was unexpected since remission is characterized
by a rather less aggressive progression whereas elevated CCL3
has been shown to be associated with increased insulitis [23].
In addition, protection from immune-mediated diabetes in
animal models was associated with decreased CCL3 concen-
trations [26]. Whether elevated CCL3 concentrations in
remitters reflect an enforced leukocyte attraction due to the
presence of more insulin producing β-cells remains specula-
tive. Interestingly, we could not observe a statistical sig-
nificant elevation of the Th2 related CCL4 in remitters that has
been described to prevent diabetes in NOD mice [24].
We investigated the relation of CCR5 ligands in type 1
diabetes in more detail by analyzing association of CCR5
ligands with β-cell function and metabolic parameters. Both
Th1 associated chemokines CCL3 and CCL5 were inversely
related with β-cell function which confirms previous work
that suggested a deleterious role of these chemokines [3,27].
Figure 3 Distribution of chemokine concentrations and metabolic parameters of patients with respect to centers. C-peptide, HbA1c,
age and chemokine concentrations of patients were classified by the enrolment of the corresponding country/center and sorted by
increasing C-peptide concentrations. Medians are presented and calculated p-values indicate that medians differ significantly (Kruskal
Wallis test). Of note, all y-axes show log values beside age which gives linear values.
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63CCL3/CCL4/CCL5, type 1 diabetes and disease progressionWe observed different associations of CCL3 and CCL5 with
metabolic parameters suggesting a differential role of these
Th1 associated chemokines in type 1 diabetes. CCL3 showed
the most prominent contribution in the association and
prospective model despite the rather stable course over time
in the entire cohort. This conception underscores the impor-
tance of analysis of clinically different subgroups. Indeed,
when classifying for remission, CCL3 revealed an opposed
longitudinal course for remitters versus non-remitters.
CCL3 showed a negative association with C-peptide and a
positive association with proinsulin that is not only a precursor
of C-peptide but has also been described as amarker for β-cell
stress [28–30]. Interestingly, in the prospective model CCL3
was negatively associated with HbA1c and might support the
assumption of enforced leukocyte attraction due to the
presence of more insulin producing β-cells and confirms
observations between CCL3 and remission. In contrast, CCL5
showed positive association with HbA1c and proinsulin but not
with C-peptide. CCL4 that is related to Th2 was negatively
associatedwithproinsulin. This finding supports the suggestion
of a protective role of CCL4 to β-cell during diabetes progres-
sion [23,24]. The missing association of CCL4 with remission
that was defined bymetabolic control and insulin requirement
might be explained by the reason that remission is caused by
different factors than just β-cell function [31,32].
Of note, the standardized protocol of the Diabetes Control
and Complications Trial was applied to determine the peak
C-peptide concentrations after mixed meal stimulation
[14,15], appreciating that some patients may have a peak
response at a slightly different time point.
Interestingly, patients separated by country/enrolling
centers revealed statistical significant differences with
respect to metabolic parameters and chemokine concentra-
tions. Whether differences occurred due to more aggressive
disease, early diagnosis due to good health care system or
environmental factors beside many others cannot be
answered in this study design. As samples were obtained
after a standardized protocol and were sent frozen to a
central facility for determination, differences of these
parameters due to centres can be excluded. Our findings
are in line with observations from others reporting country or
even site specific differences due to several reasons [21,33].
However, our data need to be interpreted with caution since
patient numbers recruited varied considerably between
centres. As discussed and suggested by others [34], multiple
regression analyses were not adjusted for centres because of
standardized protocol, central determination of outcome
variables, low center enrollment and determination of local
caused immune markers in circulation.
Taken together in this well-characterized, prospective and
unique Hvidøre cohort we present different associations of
the CCR5 ligands CCL3, CCL4 and CCL5 in type 1 diabetes.
Both Th1 related chemokines CCL3 and CCL5 were associated
with decreased β-cell function. Associations with remission
and metabolic parameters suggest a differential role in
disease progression of these two chemokines. CCL4 that
revealed negative association with proinsulin as a stress
marker might play a rather benign role.
However, it needs to be kept in mind that the results
presented here are descriptive and the outcome of associations
observed frommetabolic data and peripheral blood and thereby
a causal relationship cannot be addressed. Another topic ad-dresses implication of BMI percentiles. We applied BMI
percentiles from the United States, although the patients inves-
tigated origin from different centers mainly in Europe. This
problem of heterogeneity could be overcome by applying
country specific BMI, but theywerenot available for all patients.
We conclude that direct blockage of CCL3 and CCL5 or the
antagonism of CCR5 by maraviroc currently applied for HIV
patients may provide a new therapeutic target to ameliorate
disease progression in type 1 diabetes as has been shown in
animal models [4,5].
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